Biophytis SA today announces the completion of a capital increase trough the issue of new shares each accompanied by a share subscription warrant, with the removal of the preferential subscription rights of the Company’s existing shareholders in favor of several institutional investors, for a total gross amount of €2,015,000 (the “Issue”).
Biophytis SA announces several amendments to the bond financing announced on August 5, 2025, in joint agreement with Hexagon Capital Fund.
Biophytis announces the signing of a landmark agreement to create a Hong Kong-based joint venture, Biophytis Biopharmaceutical Holding Ltd, designed to accelerate the development and commercialization of BIO101 in sarcopenia in Asian markets.
Biophytis reports its financial results for the first half of 2025 and provides an update on its strategic outlook. Stanislas Veillet, Chief Executive Officer of Biophytis, stated: “The first half of 2025 marks a decisive milestone in the execution of our strategy. With the signing of a memorandum of understanding to create a joint venture…
Biophytis Secures Non-Dilutive Bond Financing Line of up to €1 Million Biophytis announces the establishment of a non-dilutive bond financing line for a maximum amount of €1 million with Hexagon Capital Fund, with an initial subscription of €100,000. Fullscreen Mode
Biophytis Reports 2024 Financial Results and 2025 Outlook Plans to initiate Phase 2 study in obesity and Phase 3 study in sarcopenia as soon as possible. Continued partnership strategy to support the funding of clinical programs. Strengthening of the drug discovery platform through the integration of disruptive technologies. Biophytis announced its financial results for the…
Information on the Annual Financial Statements Biophytis announces that it is not in a position to publish its 2024 annual accounts on the previously scheduled date. Biophytis will publish its 2024 annual accounts as soon as possible, by Monday, July 7 at the latest. Fullscreen Mode
Biophytis announces the temporary suspension of the trading of its shares Biophytis announces the temporary suspension of the trading of its shares by Euronext, due to the non-publication of its annual financial report for the fiscal year ended December 31, 2024. The report will be published following certification of the accounts by the statutory auditors,…
Information on the Annual Financial Statements Biophytis announces that, due to exceptional circumstances related to technical complications in the audit process, the publication of its 2024 annual financial statements has been postponed. The Company requires additional time to complete the audit and certification of its accounts. As a result, Biophytis will publish its 2024 annual…
Postponement of the publication of the annual financial statements Biophytis announces the postponement of the publication of its annual financial statements for the year ended December 31, 2024. Due to the €2.6 million refinancing operation (announced in the press release dated March 26, 2025), the Company had to focus its efforts on the related discussions…
Biophytis announces the settlement and delivery of its €2.6 million private placement NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA Biophytis announces today the settlement and delivery of its private placement in the amount of €2,599,979.72 (including the issuance premium), carried out through the issuance,…
Biophytis announces the successful completion of a €2,6 million private placement Capital increase of a total amount of approximately €2,6 million in gross proceeds by issuing 4,307,614 new shares, each with one share warrant attached, at €0,26 per unit, and 5,692,308 pre-funded warrants, each with one share warrant attached, at €0,25 per pre-funded unit; Gross…
Biophytis announces temporary suspension of the listing of its shares and share warrants prior to the completion of a refinancing transaction Biophytis announces today that the listing of its ordinary shares and share warrants on the Euronext Growth market, and its American Depositary Shares (ADS) on the OTC market, will be temporarily suspended as from the…
Biophytis extends its contract with Atlas to secure financing for its business activities Biophytis announces the extension of its bond financing agreement with Atlas, a specialized investment fund based in New York (USA), in order to secure financing for its business activities, in particular the launch of its clinical programs OBA in obesity and MYODA…
Biophytis Announces Transfer of ADSs to OTC Market ADSs delisted from Nasdaq, which will result in meaningful savings ADSs transferred to OTC Pink market; Company will apply to trade on OTCQB market Biophytis remains listed on Euronext Growth Paris as its primary trading market Biophytis annouced that on April 24, 2024, the Company received formal…
Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program Biophytis annouces that it will change the ratio of its American Depositary Shares (the “ADSs”) to Biophytis ordinary shares (the “Shares”) from one ADS representing 100 Shares, to one ADS representing 4,000 Shares (the “Ratio Change”). The effective date of the Ratio Change (the…
Biophytis announces its 2023 financial results and provides an update on its business activities Biophytis publishes its financial results for the year ended December 31, 2023, and provides an update on the progress of its various programmes. “In 2023, despite a particularly difficult financial environment for the biotech sector, we succeeded in pursuing the development…
Biophytis announces the implementation of a reverse stock split of its ordinary shares traded on Euronext Growth Biophytis announces that it has decided to implement a reverse stock split, with effect from April 2 2024, on the basis of 1 new share for every 400 held. Fullscreen Mode
Biophytis announces the drawing of the fourth tranche of ORNANE under the 2021 Atlas Contract Biophytis announces the drawing of a new tranche of Bonds Redeemable in Cash and New and Existing Shares (ORNANE) under its existing convertible bond agreement with Atlas, a specialized investment fund based in New York (United States). Fullscreen Mode
Biophytis announces the success of its capital increase with preferential subscription rights for approximately €1.96 million Biophytis announces the successful completion of its capital increase with shareholders’ pre-emptive subscription rights (DPS) through the issue of shares with redeemable share warrants (ABSAR), for an amount, including issue premium, of approximately €1.96 million (the “Capital Increase”). Stanislas…
Biophytis receives notice of delisting from Nasdaq and announces it will request a hearing before the Nasdaq Hearings Panel Biophytis announces that it has received a notice of delisting from Nasdaq. The staff of the Listing Qualifications Department has determined that the Company’s securities have not regained compliance with the minimum $2,500,000 stockholders’ equity requirement…
Biophytis announces the launch of a rights issue with maintenance of shareholders’ preferential subscription rights to continue the execution of its strategic roadmap Public offering of ABSARs: new shares with redeemable share subscription warrants (BSARs) Subscription price: €0.0093 per new share each with a subscription warrant Subscription ratio: 3 ABSARs for 8 existing shares Trading…
Biophytis releases its half-yearly accounts as of 30 June 2023 and provides an update on its operations Start of industrial development of Sarconeos (BIO101) with a view to market access in severe forms of Covid-19 (COVA) Approvals to start the Phase 3 trial in the United States and Belgium in sarcopenia (SARA), a world first,…
Biophytis Announces $3.8 Million Registered Direct Offering Fullscreen Mode
Successful capital increase for Biophytis with €2.3 million raised Biophytis is announcing it has successfully completed its fundraising round for a total amount of €2.3M through capital increases with cancellation of the shareholders’ preferential subscription rights to the benefit of professional investors up to €1.9M on the one hand, and to the benefit of individual…
Biophytis launches a round of fundraising for approximately 2 million euros Biophytis announced the launch of a round of fundraising for approximately 2 million euros based on issuing new shares for professional investors, as defined below, and retail investors (through the PrimaryBid platform) (the “Operation”). Capital increases as part of a global offering comprising an…
Biophytis announces receipt of Nasdaq Notice Biophytis announced that it has received written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) dated April 24, 2023, indicating that, based on the reported stockholders’ equity of (€1,911,000) of Biophytis as reported in its 20-F, the Company does not meet the minimum shareholders’ equity criteria…
Biophytis regains compliance with NASDAQ minimum bid price requirement Biophytis announced that it has received written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“NASDAQ”) dated April 14, 2022, indicating that Biophytis has regained compliance with the Nasdaq Global Select Market minimum bid price requirement. On October 20, 2022, the Nasdaq had notified…
Biophytis Announces 2022 Financial Results and 2023 Perspectives €11.1M of available cash and equivalents on December 31, 2022, and financing instruments for a total of €22M allowing financial visibility beyond mid 2024 Positive results of the Phase 2-3 COVA study for the treatment of severe COVID-19 with Sarconeos (BIO101) Early Access Program (EAP) submission in…
Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program Fullscreen Mode
Biophytis publishes its key financial figures as at 30 June 2022, announces a restatement of the financial statements published as of December 31st, 2021 and provides an update on the operational milestones Fullscreen Mode
Biophytis announces receipt of Nasdaq Notice Biophytis announced that it has received written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) dated October 20, 2022, indicationg that, based upon a closing bid price of less than $1.00 per share for the Company’s American Depositary Shares (“ADSs”) for the prior 30 consecutive business…
Biophytis announces the drawing of the second tranche of ORNANE under the 2021 Atlas Contract for €4 million Biophytis announces the issuance of the 160 Bonds Redeemable in Cash and New and Existing Shares (ORNANE) for a total amount of €4 million under its existing convertible bond agreement with Atlas, a specialized investment fund based…
Biophytis announces its audited financial results for the year ended December 31, 2021, and provides updates on key operational achievements as well as perspectives for 2022 Success of Nasdaq IPO in February 2021 €23.9M of available cash on December 31 2021 and new financing instruments for a total of €42M allowing financial visibility beyond mid…
Biophytis announces the drawing of the last tranche of ORNANE under the 2020 Atlas Contract for €3 million Biophytis announces the issuance of the last 120 Bonds Redeemable in Cash and New and Existing Shares (ORNANE) for a total amount of €3 million under its existing convertible bond agreement with Atlas, a specialized investment fund…
Biophytis obtains a new 10M€ loan structure with Kreos Capital Biophytis announces that the Company entered into a new loan structure with Kreos Capital. Stanislas Veillet, CEO of BIOPHYTIS, stated: “This transaction allows us to fund the final steps of our COVA phase 2-3 study in COVID-19, mostly for registration under Emergency Use Authorization with…
Biophytis to Present Full Results from the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 – October 2, 2021 Biophytis today announces it will present full results from the SARA-INT Phase 2 trial of Sarconeos (BIO101) in Sarcopenia at the…
Biophytis announces new convertible bonds financing up to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million
Biophytis receives €980,000 DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry AMD
Biophytis Reports 2020 Full Year Results
Biophytis Announces Closing of ADS Offering on Nasdaq Capital Market
Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market
Biophytis Announces Temporary Trading Halt of its Shares and Share Warrants on Euronext Growth
Biophytis Announces Trading Resumption of its Ordinary Shares and Share Warrants on Euronext
Biophytis Announces the Launch of its Proposed Public Offering and Nasdaq Listing
Biophytis Announces Plan to Publicly File Later Today Registration Statement for Proposed Initial Public Offering in the United States
Biophytis Trading will resume on September 30, 2020 at 3.00pm CEST. Read the Press Release
Biophytis announces a € 10 million capital increase through private placement. Read the Press Release
Biophytis shares and BSA trading is suspended pending a new press release. Read the Press Release
Biophytis Reports H1 2020 Financial Results and Provides Business Update. Read the Press Release
Biophytis announces the issuance of a €3 million tranche of ORNANE. Read the Press Release
Biophytis announces a € 6.1 million capital increase through private placement. Read the Press Release
Biophytis announces the issuance of a €3 million tranche of ORNANE. Read the Press Release
Biophytis successfully completes a € 4 million capital increase to strengthen its financial structure. Read the Press Release
Biophytis announces the issue of 2,050,000 new shares in a capital increase reserved for NEGMA. Read the Press Release
Biophytis shares resume trading following the implementation of measures ordered in connection with a dispute with NEGMA. Read the Press Release
Biophytis shares and BSA trading is suspended pending a new press release. Read the Press Release
Biophytis Successfully Closes its Public Offering of Share Subscription Warrants (BSA). Read the Press Release
Correction – Biophytis launches a Public Offering of Share Subscription Warrants (BSA) with an Irreducible Priority Subscription Period for Existing Shareholders. Read the Press Release
Biophytis Announces Launch of a Public Offering of Share Subscription Warrants (BSA) with an Irreducible Priority Subscription Period for Existing Shareholders. Read the Press Release
Biophytis has signed a New Convertible Bond Financing of €24 million from Atlas to Continue the Development of Sarconeos (BIO101). Read the Press Release
2019 Annual Financial Report made available. Read the Press Release
Biophytis Reports 2019 Full Year Results and Provides Operational Update. Read the Press Release
Biophytis Trading will resume on February 14th, 2020 at 09:00 CET. Read the Press Release
Biophytis successfully completes a € 3.3 million capital increase to strengthen its financing structure. Read the Press Release
Biophytis shares trading is suspended pending a new press release. Read the Press Release
Biophytis announces the issuance of a €3 million tranche of ORNANEBSA. Read the Press Release
